Coyne Scientific:  Genetic Diversity, In Vitro

Because...
  Genetic differences among humans drive differences in their responses to pharmaceutical drugs
...and...
  Cardiomyocytes derived from the iPSCs of specific humans recapitulate the responses of their hearts when exposed to drugs in clinic
…it’s now possible to change the paradigm in pharmaceutical drug development...
  Coyne Scientific’s unique platform – delivering genetic diversity, in vitro – opens the door to game-changing advances in the safety and cost of developing new drugs, including:
    Early and accurate cardiac risk assessment, based on pre-clinical testing of large numbers of identically-prepared cell lines reflecting representative samples of target populations, not just one random cell line
    Early detection – and early termination or modification – of candidate drugs that would later fail in clinical trials
    Enhanced safety for target populations that are not adequately protected by clinical trials
    Deeper understanding of pharmacodynamic drug-drug interaction effects
    Practical applications in the arena of personalized toxicology
Intrigued?  Read on...

Our Company

Coyne Scientific (“CoyneSci”) is an emerging biotech services company seeking to make a major difference in worldwide health by…
Read more...

Our Perspective

The cost of developing a new drug has recently been estimated at $2.6 billion. A critical, but largely unrecognized, reason why the cost is so high is that…
Read more...

In The News

Check back regularly for the latest news and announcements regarding…
Read more...